NCT05941507 2025-09-24A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid TumorsLigaChem Biosciences, Inc.Phase 1/2 Recruiting300 enrolled
NCT04672434 2024-12-09Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor MalignanciesSymphogen A/SPhase 1 Completed48 enrolled